Skip to main content
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc

Track IRWD — free
$4.72 -0.06 (-1.34%)
Market Cap
$767.33M
Shares
165.55M
Volume · Nov 19 912.12K Avg daily vol (3M) 2.1M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.78 Open$4.85 Day$4.70–4.94 52W close$3.04–5.39 Avg vol 30d2.3M Short int14.9M · 9.0% of shares · 9.8d Short vol44% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month net income reaches $151.9 million

Ironwood Pharmaceuticals reported net income of $151.9 million for the nine months ended September 30, 2026. It initiated the 24-week STARS-2 Phase III trial in June 2026 and plans a regulatory filing in 2029.

Revenue $133.04M ▲ 9.0% Net income $59.84M ▲ 49.3% Diluted EPS $0.36 ▲ 56.5%
Read from the MD&A section
4 source passages
On April 7, 2008, we changed our name to Ironwood Pharmaceuticals, Inc. For the three and nine months ended September 30, 2026, we recorded net income of $59.8 million and $151.9 million, respectively. STARS-2 is a 24-week global, randomized, double-blind, placebo-controlled trial. In June 2026, we initiated STARS-2 and are actively recruiting patients. Subject to the results of STARS-2, we plan to file for regulatory approval in 2029. Open the document at this passage
Nov 5
Earnings call
Linzess guidance raised as adjusted EBITDA hits record

Ironwood Pharmaceuticals raised its 2026 Linzess net sales guidance to $1.20 to $1.25 billion, representing growth of more than 35% year-over-year, and reported record adjusted EBITDA of $98 million.

3 source passages
At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q3 2026 Investor Update Conference Call. These factors support the raise of our full-year Linzess net sales guidance by $50 million to $1.20 to $1.25 billion. Representing growth of more than 35% year-over-year. In the third quarter, total revenue was $133 million, GapNet income was $60 million, and adjusted EBITDA was a record of $98 million. Open the document at this passage
Nov 5
Current report 8-K
Raises 2026 guidance after strong LINZESS and EBITDA performance

Ironwood Pharmaceuticals raised 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion, total revenue to $485 - $510 million and adjusted EBITDA to greater than $350 million. Third-quarter revenue was $133.0 million and adjusted EBITDA was $97.9 million.

Financial results
4 source passages
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update. Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 - $1.25 billion, representing greater than 35% increase year-over-year; Raises total 2026 revenue guidance to $485 - $510 million and adjusted EBITDA guidance to greater than $350 million – Total revenue in the third quarter of 2026 was $133.0 million, compared to $122.1 million in the third quarter of 2025. Adjusted EBITDA was $97.9 million in the third quarter of 2026, compared to $81.8 million in the third quarter of 2025. Open the document at this passage
Oct 16
Current report 8-K Events of Oct 12
Director or officer change, or executive pay

On October 12, 2026, Ironwood Pharmaceuticals appointed Chief Commercial Officer Tammi Gaskins as CEO effective January 1, 2027, succeeding Tom McCourt, who retires after 17 years and will remain a director.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$400.30M
Trailing 12 months
Net income (TTM)
$149.63M
Trailing 12 months
Revenue growth YoY
+9.0%
Year over year
Operating margin
62.9%
Trailing 12 months
P / E (TTM)
5.3
Trailing earnings · reciprocal yield 18.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$59.10M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-5.4%
Year over year · fewer shares
Price change (1Y)
+53.7%
Trailing year
Short interest
9.0%
Latest settlement · 9.8 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Ironwood raised 2026 guidance as LINZESS prescription demand remained strong, commercial margin improved, and Q3 revenue, net income, and adjusted EBITDA were $133 million, $60 million, and a record $98 million, respectively. The company generated $130.8 million from operations and advanced the STARS-2 trial; key risks include unfavorable net pricing, trial and regulatory uncertainty, reimbursement pressure, and competition.

Bullish
  • + Full-year 2026 LINZESS net sales guidance was raised to $1.20-$1.25 billion, total revenue guidance to $485-$510 million, and adjusted EBITDA guidance to greater than $350 million.
  • + Q3 2026 total revenue was $133 million, GAAP net income was $60 million, and adjusted EBITDA was a record $98 million.
  • + LINZESS Q3 2026 prescription demand increased 4.9%.
  • + LINZESS commercial margin improved to 79.8% in Q3 2026 from 75.9% in Q3 2025.
  • + Ironwood generated $130.8 million from operations in Q3 2026.
  • + The STARS-2 trial's planned activation of more than 100 sites across 22 countries is on track.
Bearish
  • − LINZESS Q3 2026 net sales growth was constrained by a low single-digit net price decline caused by unfavorable gross-to-net rebate reserves.
  • − Apraglutide's planned 2029 regulatory filing is contingent on the results of the confirmatory STARS-2 trial.
  • − Apraglutide may not receive regulatory approval from the FDA or other regulatory agencies.
  • − Clinical programs may be delayed or discontinued because of safety, tolerability, enrollment, manufacturing, economic, or other reasons.
  • − Unfavorable pricing and reimbursement policies could hinder or prevent LINZESS's commercial success.
  • − Apraglutide faces competition from new products that may provide different or better treatment alternatives.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +21%
above
Price vs 50-day avg +19%
above
RSI (14) 71
overbought
MACD trend Positive
52-week position 74%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +35%
trailing
6-month return +34%
trailing
YTD return +42%
this year
Relative strength +37%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Golden cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +43 funds added
Insider flow Distributing
Net -$28.5K over 90 days · 100% sells
Short interest Falling
8.98% of shares out · ▼ -6.5% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
232 holders — mid 3-yr range
Squeeze score 69
elevated · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
EPS growth +1400%
Y/Y
Free cash flow $127.0M
Valuation P/E 5.2
below peers
Buyback $32.4M
remaining
Balance sheet $110.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −44%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 6
Latest guidance · from the Earnings Call filed Nov 5, 2026
full year 2026
U.S. net sales $1.2B – $1.25B
Adjusted EBITDA Non-GAAP at least $350M
Total revenue Raised $485M – $510M
Aug 6, 2026 $460M – $485M changed to Nov 5, 2026 $485M – $510M
prior FY $296.15M midpoint +68.0% Y/Y
end of 2026
Total debt at year end up to $300M
remainder of the year
Margin 80%
Previous outlook earlier release · from the 8-K filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

U.S. LINZESS Net Sales · 2026 $1.15B – $1.2B
Adjusted EBITDA · 2026 at least $310M
Guided vs delivered · last 6 settled
Total Revenue full year 2025
guided $290M – $310M
$296.15M In line
Total Revenue FY 2024
guided $350M – $375M
$351.41M In line
Total Revenue 2023
guided $435M – $450M
$442.74M In line
Total Revenue 2022 Guidance
guided $420M – $430M
$410.6M Miss −3.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+21% Bullish
Price vs 50-day avg
+19% Bullish
RSI (14)
71 Bearish
MACD trend
Positive Bullish
52-week position
74% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) Golden cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +43 funds added
Insider flow Distributing
Net -$28.5K over 90 days · 100% sells
Short interest Falling
8.98% of shares out · ▼ -6.5% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
232 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $5 · 74% Range high $5
vs 200-day avg +21% vs 50-day avg +19% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $83M Q2 2026 —
Adjusted EBITDA guidance non-GAAP $310M Updated 2026 Guidance (August 2026) —
LINZESS commercial margin 78% Q2 2026 —
LINZESS U.S. brand collaboration net profit $214.6M Q2 2026 —
LINZESS U.S. collaboration revenue to Ironwood $110M Q2 2026 —
LINZESS U.S. net sales $282.3M Q2 2026 —
Total LINZESS demand 59.8M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IRWD
Ironwood Pharmaceuticals Inc
this stock
$767.33M +41.8% +8.9% 5.2 9.0%
TAK
Takeda Pharmaceutical Co Ltd
$67.96B +36.4% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.28B +35.3% +4.3% 96.0 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
232
% held
92.8%
Net QoQ
-6.9M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
227
View
Short & Settlement
Short Interest Falling
Shares short
14.9M
Days to cover
9.8d
Change
-1.0M sh
View
Short Volume
Short vol %
44%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
2.3K
Value
$8.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
44.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$28.5K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$296.2M
Net income (FY)
$24.0M
EPS diluted
$0.15
View
Buybacks
Authorized
$150.0M
Remaining
$32.4M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
21

Ironwood Pharmaceuticals reported net income of $151.9 million for the nine months ended September 30, 2026. It initiated the 24-week STARS-2 Phase III trial in June 2026 and plans a regulatory filing in 2029.

View
Proposed Sales
Value
$32.3K
Shares
6.7K
Filed
Nov 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Ironwood Pharmaceuticals Raises F…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
IRWD -1.9% +34.7% +33.9% +36.6% +41.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +2.1% +40.2% +37.4% +40.0% +34.8%

Capital returns

Buyback program · as of Mar 31, 2022
Authorized
$150.00M
Spent (derived)
$117.60M
Remaining
$32.40M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 243 filings 221 filers Visit website Investor relations